Individualized Information Sharing Important in All Stages of Cancer Care

Share this content:

the Cancer Therapy Advisor take:

Appropriate, individualized sharing of information for patients with cancer was determined to be important during treatment, at the time of hospital discharge, and in primary care, according to an article published online in the journal European Journal of Cancer Care.

The authors of this study aimed to explore cancer survivors’ experiences regarding information they were given about potential long-term and late effects of pelvic radiotherapy.

Twenty-eight cancer survivors who had received pelvic radiotherapy for a range of cancers (1-11 years prior to the study) were interviewed. Participants from a larger questionnaire survey of patients treated at another hospital were also interviewed.

Results showed the patients acknowledged the potential ability of information to reassure and inform patients, but also identified its ability to produce undesirable effects or raise anxieties about future problems.

Furthermore, the participants identified the importance of the timing, amount of information provided, and context of their situations—value was also placed on information based on personal experience.

Bristol-Myers Squibb has announced the early closure of its phase 3 CheckMate-025 trial evaluating n
Appropriate, individualized sharing of information for patients with cancer was determined to be important during all stages.
As more patients survive cancer for longer term, the long-term and late effects of treatments become increasingly important issues for cancer survivors and providing information to enable survivors to recognise and manage them becomes an increasingly pressing challenge for health care professionals.
READ FULL ARTICLE From Wiley Online Library

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters